The Asia Pacific acne medication market was valued at US$ 1,508.26 in 2022 and is expected to reach US$ 2.67 billion by 2030; it is estimated to register at a CAGR of 7.4% from 2023 to 2030.
It has signed extension agreements to the license and supply contracts for WINLEVI (clascoterone) cream 1 percent, enlarging the geographical scope to encompass Australia, New Zealand, Japan, Brazil, Mexico, and Russia. In 2023, Torii Pharmaceutical Co., Ltd. and Nogra Pharma, a clinical-stage biotechnology company creating novel therapeutics for immune-inflammatory-mediated diseases, announced an out-licensing agreement for the development and commercialization of NAC-GED-0507 for the treatment of acne vulgaris in Japan.
Novel drug launches also include advanced formulations with improved efficacy, enhanced safety profiles, and reduced side effects, catering to the evolving needs of individuals seeking effective acne management. According to a statement released in October 2023 by Bausch Health Companies Inc. and its dermatology business - Ortho Dermatologics - the US Food and Drug Administration (FDA) approved the New Drug Application for CABTREO topical gel composed of 1.2%, 0.15%, and 3.1% clindamycin phosphate, adapalene, and benzoyl peroxide, respectively. This is a topical treatment indicated for acne vulgaris in patients aged 12 or older. CABTREO is the first and only topical triple combination acne therapy approved by the FDA, which is offered in a fixed-dose form. The company aims to make this gel available for patients in Q1 2024.
The introduction of novel medications, such as retinoids, anti-androgens, and immune modulators, has further expanded the therapeutic options available for healthcare professionals and individuals dealing with acne. The continuous introduction of new drugs stimulates competition, fosters innovation, and encourages research and development investments within the dermatological pharmaceutical industry. The heightened focus on personalized and targeted treatment approaches for treating acne forms a foundation for the advent of novel drugs to improve patient outcomes and satisfaction. Thus, the launch of novel drugs significantly contributes to the progress of the Asia Pacific acne medication market.
The increased prevalence of acne, possibly linked to lifestyle changes and environmental factors, has further fueled demand for effective treatments. As Chinese consumers prioritize skincare for their well-being, pharmaceutical companies are introducing innovative formulations to meet this burgeoning demand. Thus, advanced technologies, economic factors, and evolving healthcare priorities are together steering the acne medication market toward unprecedented growth in China.
Launch of Novel Drugs Boosts Asia Pacific Acne Medication Market
Innovative pharmaceutical developments, including topical and systemic medications, have fundamentally reshaped treatment approaches for acne. In 2024, the Australian Therapeutic Goods Administration (TGA) approved Winlevi (clascoterone) cream 1% from Sun Pharmaceutical of India to treat acne vulgaris in individuals 12 years of age and older. In 2022, Sun Pharmaceutical Industries broadened the scope of its collaboration with Cassiopea with respect to an acne treatment.It has signed extension agreements to the license and supply contracts for WINLEVI (clascoterone) cream 1 percent, enlarging the geographical scope to encompass Australia, New Zealand, Japan, Brazil, Mexico, and Russia. In 2023, Torii Pharmaceutical Co., Ltd. and Nogra Pharma, a clinical-stage biotechnology company creating novel therapeutics for immune-inflammatory-mediated diseases, announced an out-licensing agreement for the development and commercialization of NAC-GED-0507 for the treatment of acne vulgaris in Japan.
Novel drug launches also include advanced formulations with improved efficacy, enhanced safety profiles, and reduced side effects, catering to the evolving needs of individuals seeking effective acne management. According to a statement released in October 2023 by Bausch Health Companies Inc. and its dermatology business - Ortho Dermatologics - the US Food and Drug Administration (FDA) approved the New Drug Application for CABTREO topical gel composed of 1.2%, 0.15%, and 3.1% clindamycin phosphate, adapalene, and benzoyl peroxide, respectively. This is a topical treatment indicated for acne vulgaris in patients aged 12 or older. CABTREO is the first and only topical triple combination acne therapy approved by the FDA, which is offered in a fixed-dose form. The company aims to make this gel available for patients in Q1 2024.
The introduction of novel medications, such as retinoids, anti-androgens, and immune modulators, has further expanded the therapeutic options available for healthcare professionals and individuals dealing with acne. The continuous introduction of new drugs stimulates competition, fosters innovation, and encourages research and development investments within the dermatological pharmaceutical industry. The heightened focus on personalized and targeted treatment approaches for treating acne forms a foundation for the advent of novel drugs to improve patient outcomes and satisfaction. Thus, the launch of novel drugs significantly contributes to the progress of the Asia Pacific acne medication market.
Asia Pacific Acne Medication Market Overview
The Asia Pacific acne medication market is segmented into China, Japan, India, Australia, and South Korea. This region is expected to record the fastest CAGR during the forecast period. The projected acne medication market growth in the region is ascribed to the burgeoning interest of major players in expanding their presence in developing regions and the flourishment of the skincare industry. China’s nation's rising disposable income has heightened consumer spending on skincare, contributing to the expansion of the acne medication market size.The increased prevalence of acne, possibly linked to lifestyle changes and environmental factors, has further fueled demand for effective treatments. As Chinese consumers prioritize skincare for their well-being, pharmaceutical companies are introducing innovative formulations to meet this burgeoning demand. Thus, advanced technologies, economic factors, and evolving healthcare priorities are together steering the acne medication market toward unprecedented growth in China.
Asia Pacific Acne Medication Market Segmentation
- The Asia Pacific acne medication market is segmented based on therapeutic class, formulation, type, acne type, distribution channel, and country.
- Based on therapeutic class, the Asia Pacific acne medication market is segmented into retinoids, benzoyl peroxide, antibiotics, salicylic acid, and others. The retinoids segment held the largest share in 2022.
- In terms of formulation, the Asia Pacific acne medication market is bifurcated into topical medication and oral medication. The topical medication segment held a larger largest share in 2022.
- By type, the Asia Pacific acne medication market is bifurcated into prescription medicine and over-the-counter medicine. The prescription medicine segment held a larger largest share in 2022.
- Based on acne type, the Asia Pacific acne medication market is bifurcated into non-inflammatory acne and inflammatory acne. The inflammatory acne segment held a larger share in 2022.
- In terms of distribution channel, the Asia Pacific acne medication market is segmented into pharmacies and drug stores, retail stores, and e-commerce. The pharmacies and drug stores segment held the largest share in 2022.
- Based on country, the Asia Pacific acne medication market is categorized into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific acne medication market in 2022.
- Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, Mayne Pharma Group Ltd, Almirall SA, Johnson & Johnson, Bausch Health Companies Inc, Galderma SA, Pfizer Inc, GSK Plc, and Viatris Inc are some of the leading companies operating in the Asia Pacific acne medication market.
Market Highlights
- Based on therapeutic class, the Asia Pacific acne medication market is segmented into retinoids, benzoyl peroxide, antibiotics, salicylic acid, and others. The retinoids segment held 33.6% share of the Asia Pacific acne medication market in 2022, amassing US$ 506.99 million. It is projected to garner US$ 984.12 million by 2030 to expand at 8.7% CAGR during 2023-2030.
- In terms of formulation, the Asia Pacific acne medication market is bifurcated into topical medication and oral medication. The topical medication segment held 68.6% share of the Asia Pacific acne medication market in 2022, amassing US$ 1.03 billion. It is estimated to garner US$ 1.90 billion by 2030 to expand at 8.0% CAGR during 2023-2030.
- The prescription medicine segment held 65.3% share of Asia Pacific acne medication market in 2022, amassing US$ 984.72 million. It is predicted to garner US$ 1.80 billion by 2030 to expand at 7.9% CAGR during 2023-2030.
- The inflammatory acne segment held 54.6% share of the Asia Pacific acne medication market in 2022, amassing US$ 823.08 million. It is projected to garner US$ 1.49 billion by 2030 to expand at 7.7% CAGR during 2023-2030.
- In terms of distribution channel, the Asia Pacific acne medication market is segmented into pharmacies and drug stores, retail stores, and e-commerce. The pharmacies and drug stores segment held 49.6% share of the Asia Pacific acne medication market in 2022, amassing US$ 748.80 million. It is estimated to garner US$ 1.40 billion by 2030 to expand at 8.2% CAGR during 2023-2030.
- China held 29.5% share of Asia Pacific acne medication market in 2022, amassing US$ 445.39 million. It is projected to garner US$ 943.00 million by 2030 to expand at 9.9% CAGR during 2023-2030.
Reasons to Buy
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific acne medication market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in Asia Pacific acne medication market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. Asia Pacific Acne Medication Market Landscape
5. Asia Pacific Acne Medication Market - Key Market Dynamics
7. Asia Pacific Acne Medication Market Analysis - by Therapeutic Class
8. Asia Pacific Acne Medication Market Analysis - by Formulation
9. Asia Pacific Acne Medication Market Analysis - by Type
10. Asia Pacific Acne Medication Market Analysis - by Acne Type
11. Asia Pacific Acne Medication Market Analysis - by Distribution Channel
12. Asia Pacific Acne Medication Market - Country Analysis
13. Acne Medication Market- Industry Landscape
14. Company Profiles
15. Appendix
List of Tables
List of Figures
Companies Mentioned
Some of the leading companies in the Asia Pacific Acne Medication market include:- Teva Pharmaceutical Industries Ltd
- Mayne Pharma Group Ltd
- Almirall SA
- Johnson & Johnson
- Sun Pharmaceutical Industries Ltd
- Bausch Health Companies Inc
- Galderma SA
- Pfizer Inc
- GSK Plc
- Viatris Inc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 128 |
| Published | August 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 1.5 Billion |
| Forecasted Market Value ( USD | $ 2.67 Billion |
| Compound Annual Growth Rate | 7.4% |
| Regions Covered | Asia Pacific |
| No. of Companies Mentioned | 11 |
